Scientists in the Democratic Republic of Congo (DRC) are testing an Ebola vaccine (Ervebo), originally designed for the Zaire species, against the Bundibugyo virus, which is causing the current outbreak, to see if it offers any protection.

• The study, named BRAVO, involves 20,000 frontline workers in Ituri and North Kivu provinces.
• Key organizations involved include Médecins Sans Frontières (MSF), Epicentre, the DRC Ministry of Health, and the Africa CDC.
• While preliminary data suggest potential cross-protection, the World Health Organization (WHO) emphasizes that it's not yet known if Ervebo provides clinically meaningful protection against Bundibugyo and recommends its use only within research protocols.